The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Increase In Market Value Is Predicted For The Hepatitis B Virus (HBV) Capsid Inhibitors Market During The 2026–2030 Period?
The hepatitis b virus (hbv) capsid inhibitors market size has seen swift expansion in recent years. This market is set to increase from $0.52 billion in 2025 to $0.59 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.7%. The surge observed in the past can be ascribed to the extensive global impact of chronic hepatitis B infection, the inadequacies of current antiviral treatments, the early positive clinical validation of capsid inhibitors, heightened funding for virology research, and increasing activity within pharmaceutical pipelines.
The hepatitis b virus (hbv) capsid inhibitors market is projected to experience substantial growth in the upcoming years. By 2030, its value is expected to reach **$0.98 billion**, demonstrating a compound annual growth rate (CAGR) of **13.4%**. This anticipated expansion during the forecast period is attributed to the increased adoption of combination regimens with immunotherapies, growing investment in curative HBV treatments, a rise in regulatory approvals for innovative antivirals, expanding global screening programs, and advancements in next-generation capsid inhibitors. Key trends for this period include a heightened focus on functional cure strategies for HBV, accelerated development of capsid assembly modulators, evolving combination therapy approaches, the expansion of late-stage clinical pipelines, and improved targeting of viral replication pathways.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30294&type=smp
Which Growth Drivers Are Expected To Support The Hepatitis B Virus (HBV) Capsid Inhibitors Market Forward?
The rising incidence of hepatitis B virus infections is projected to fuel expansion within the hepatitis B virus (HBV) capsid inhibitors market in the coming period. Hepatitis B Virus (HBV) infections are defined as hepatic ailments triggered by the hepatitis B virus, capable of manifesting as acute or long-term conditions. These infections transmit via exposure to contaminated blood or bodily fluids and can culminate in severe health issues like liver cirrhosis or liver cancer. The heightened occurrence of Hepatitis B Virus (HBV) infections largely stems from inadequate vaccination rates, leaving significant segments of the populace vulnerable and facilitating the virus’s transmission via contact with infected blood or bodily fluids. Hepatitis B virus (HBV) capsid inhibitors combat hepatitis B virus (HBV) infections by interfering with the development and construction of the viral capsid, consequently hindering viral replication and decreasing the dissemination of the infection internally. As an illustration, a report released by the World Health Organization (WHO), a Switzerland-based intergovernmental body, in April 2024, indicated that by the end of 2022, merely 13% of those suffering from chronic hepatitis B had been diagnosed, with around 3% (7 million) having undergone antiviral therapy. Regarding hepatitis C, 36% of impacted individuals had received a diagnosis, and 20% (12.5 million) were undergoing curative treatment. These figures fall significantly short of the worldwide objective to treat 80% of individuals with chronic hepatitis B and C by 2030. Consequently, the expanding prevalence of hepatitis B virus infections is propelling the advancement of the hepatitis B virus (HBV) capsid inhibitors market.
What Segment Categories Are Evaluated In The Hepatitis B Virus (HBV) Capsid Inhibitors Market Study?
The hepatitis b virus (hbv) capsid inhibitors market covered in this report is segmented –
1) By Drug Type: Core Protein Allosteric Modulators (CpAMs), Capsid Assembly Modulators, Other Drug Types
2) By Application: Chronic Hepatitis B, Acute Hepatitis B, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By End-User: Hospitals, Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Core Protein Allosteric Modulators (CpAMs): Class I Core Protein Allosteric Modulators (CpAMs), Class II Core Protein Allosteric Modulators (CpAMs)
2) By Capsid Assembly Modulators: Direct Capsid Assembly Modulators, Indirect Capsid Assembly Modulators
3) By Other Drug Types: Novel Capsid Inhibitors, Combination Therapies, Experimental Mechanism-Based Inhibitors
What Trends Are Influencing The Future Of The Hepatitis B Virus (HBV) Capsid Inhibitors Market?
Leading companies active in the hepatitis B virus (HBV) capsid inhibitors market are prioritizing the advancement of technologies such as oral small molecule capsid assembly modulators. These innovations are being developed to improve antiviral efficacy, enhance patient compliance, and achieve sustained viral suppression. Oral small-molecule capsid assembly modulators are characterized as antiviral agents taken by mouth that interfere with the assembly process of the hepatitis B virus (HBV) capsid, consequently blocking its replication and reducing viral activity in the body. For instance, in July 2024, Aligos Therapeutics, Inc., a US-based clinical-stage biopharmaceutical company, partnered with Xiamen Amoytop Biotech Co., Ltd., a China-based biopharmaceutical company. This collaboration led to the launch of a clinical trial designed to evaluate pioneering treatment candidates for chronic hepatitis B (CHB), with the goal of leveraging Aligos’s sophisticated capsid assembly modulator technology to increase antiviral efficacy and accelerate the development of next-generation HBV therapies. This launch signifies a key progression in Aligos’s mission to create effective and potentially curative treatments for patients living with chronic hepatitis B.
Which Organizations Are Involved In The Hepatitis B Virus (HBV) Capsid Inhibitors Market?
Major companies operating in the hepatitis b virus (hbv) capsid inhibitors market are Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Novotech Health Holdings Pte. Ltd, Enanta Pharmaceuticals Inc., Assembly Biosciences Inc., Arbutus Biopharma Corporation, Aligos Therapeutics Inc., Qilu Pharmaceutical Co Ltd., Chia Tai Tianqing Pharmaceutical Group Co Ltd., Hepion Pharmaceuticals Inc., Shanghai Zhimeng Biopharma Inc., Antios Therapeutics, Bluejay Therapeutics Inc., Core Biopharma Inc., Door Pharmaceuticals, Shanghai Longwood Biopharmaceuticals Co. Ltd., Zhimeng Biopharma Inc.
Access The Complete Hepatitis B Virus (HBV) Capsid Inhibitors Market Report:
What Is The Largest Regional Market In The Hepatitis B Virus (HBV) Capsid Inhibitors Market?
Asia-Pacific was the largest region in the hepatitis B virus (HBV) capsid inhibitors market in 2025. The regions covered in the hepatitis b virus (hbv) capsid inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Hepatitis B Virus (HBV) Capsid Inhibitors Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=30294&type=smp
Browse Through More Reports Similar to the Global Hepatitis B Virus (HBV) Capsid Inhibitors Market 2026, By The Business Research Company
Hepatitis B Virus Hbv Market Report 2026
https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report
Preventive Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report
Chronic Hepatitis B Market Report 2026
https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model